5:37 PM
 | 
May 28, 2013
 |  BC Extra  |  Top Story

Re-adjudication replays RECORD results

An independent re-adjudication of the RECORD cardiovascular outcomes trial of Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) showed that the diabetes drug was not associated with a significantly increased risk of cardiovascular events. The outcomes were consistent with the original analysis of the drug. The re-adjudication, which will be...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >